利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.017 seconds)

    BENZOFURAN-DERIVED HIV PROTEASE INHIBITORS
    2.
    发明申请
    BENZOFURAN-DERIVED HIV PROTEASE INHIBITORS 审中-公开
    苯唑来衍生的HIV蛋白酶抑制剂

    公开(公告)号：WO2008115894A1

    公开(公告)日：2008-09-25

    申请号：PCT/US2008/057281

    申请日：2008-03-17

    Applicant: SEQUOIA PHARMACEUTICALS ,  EISSENSTAT, Michael

    Inventor： EISSENSTAT, Michael

    IPC: A61K31/34 ,  A61K31/335 ,  A61K31/425

    CPC classification number: C07D493/04

    Abstract: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

    Abstract translation: 提供抗驱虫和多药耐药的逆转录病毒蛋白酶抑制剂。 还提供了包含这些化合物的药物组合物，以及使用这些化合物治疗哺乳动物HIV感染的方法。

    LONG ACTING BIOLOGICALLY ACTIVE CONJUGATES
    9.
    发明申请
    LONG ACTING BIOLOGICALLY ACTIVE CONJUGATES 审中-公开

    公开(公告)号：WO2004085505A3

    公开(公告)日：2004-10-07

    申请号：PCT/US2004/008847

    申请日：2004-03-24

    Applicant: SEQUOIA PHARMACEUTICALS, INC. ,  SILVA, Abelardo ,  ERICKSON, John, E. ,  EISSENSTAT, Michael ,  AFONINA, Elena ,  GULNIK, Sergei

    Inventor： SILVA, Abelardo ,  ERICKSON, John, E. ,  EISSENSTAT, Michael ,  AFONINA, Elena ,  GULNIK, Sergei

    IPC: A61K38/00

    Abstract: The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.

Patent Agency Ranking